Skip to main content

Study the therapeutic and preventive potential of targeting oncogenic mutations with CRISPR-Cas9 technology

Project description

Treatment for oncogene addiction could be on the horizon

Cancer is the second leading cause of death globally and incidence and mortality are increasing. Within the last decade, scientists have discovered what may be the target for a silver bullet in many cases of cancer. While most cancers are characterised by multiple oncogenic mutations, a growing body of evidence demonstrates that many cancers are sensitive to inhibition of a single one of these. The term 'oncogene addiction' was coined to express a cancer's dependency on this single carcinogenic protein or pathway to maintain malignancy. The EU-funded Genetic Vaccine project is exploiting advanced technology to induce targeted mutations in select oncogenes. Effectiveness will be tested in an animal model of cancer.

Field of science

  • /natural sciences/biological sciences/genetics and heredity/genome
  • /natural sciences/biological sciences/genetics and heredity/mutation
  • /medical and health sciences/clinical medicine/cancer

Call for proposal

H2020-MSCA-IF-2018
See other projects for this call

Funding Scheme

MSCA-IF-EF-RI - RI – Reintegration panel

Coordinator

UNIVERSIDAD DE GRANADA
Address
Cuesta Del Hospicio Sn
18071 Granada
Spain
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 160 932,48